Eligible to Act Isn’t Allowed to Act: Rob Merrill on AI in Life Sciences
The UK and EU are moving to lifecycle oversight of AI. Rob explains what that means for biopharma, and how TFives proves each AI decision was approved.
Closing the Pharma AI Compliance Gap: AI, Agencies and the Approved Record
Where approvals, AI output and agency execution drift apart, and how one approved record closes the gap.
Some of Pharma’s Biggest AI Compliance Deadlines Just Got Pushed Back
The EU AI Act and Section 504 deadlines moved. The bar didn’t. Three moves for the next 18 months, with Rob Merrill and Dr. Nastaran H.
How Evidence-First Architecture Gets Life-Sciences AI Through Regulatory Gates
Why evidence-first architecture helps life-sciences AI pass regulatory review.
How to Shift Compliance Left and Transform It Into Competitive Advantage
Moving compliance earlier in the process, and turning it into an advantage.
The $1.2 Million Lesson That Changed Life Sciences Compliance Forever
The costly lesson behind TFives’ approach to life sciences compliance.
The Economics of Replay: How to Catch Compliance Failures Before the FDA Does
Why replaying AI decisions catches compliance failures before an inspector does.
CMS Aggregate Spend Reporting: The Case for an Insourced Model
The case for running CMS aggregate spend reporting in-house.
Precise Pharmaceutical Call Planning: Generative AI-Led HCP Microsegments for Hyper-Personalized Interactions
Using generative AI to build HCP psychographic and personality microsegments for call planning.